Pharmaceutical Treatment of Amyotrophic Lateral Sclerosis Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown etiology, causing progressive paralysis, and typically leading to death within 2 to 5 years of diagnosis. At the present time, there is no way to stop or even substantially slow the inexorable worsening of this disease. While many ... Article
Article  |   June 01, 2000
Pharmaceutical Treatment of Amyotrophic Lateral Sclerosis
Author Affiliations & Notes
  • Valerie A. Cwik, MD
    University of Arizona Health Sciences Center, Tucson
Article Information
Articles
Article   |   June 01, 2000
Pharmaceutical Treatment of Amyotrophic Lateral Sclerosis
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, June 2000, Vol. 10, 11-16. doi:10.1044/nnsld10.2.11
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, June 2000, Vol. 10, 11-16. doi:10.1044/nnsld10.2.11
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown etiology, causing progressive paralysis, and typically leading to death within 2 to 5 years of diagnosis. At the present time, there is no way to stop or even substantially slow the inexorable worsening of this disease. While many neurologic diseases remain untreatable, the need for an effective treatment for ALS is particularly compelling because of its uniformly fatal outcome in the course of just a few years.
ALS affects populations worldwide. With incidence rates ranging from 0.2 to 2.4 per 100,000 population and prevalence rates estimated at 1 to 7 per 100,000, ALS is considered a rare disease. The majority of patients have sporadic ALS; however, a familial form of the disease occurs in 5–10% of patients and is usually inherited in an autosomal dominant manner.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
Become a SIG Affiliate
Pay Per View
Entire SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders content & archive
24-hour access
This Issue
24-hour access
This Article
24-hour access
We've Changed Our Publication Model...
The 19 individual SIG Perspectives publications have been relaunched as the new, all-in-one Perspectives of the ASHA Special Interest Groups.